Post by marriott on Oct 10, 2022 23:29:06 GMT
Some thoughts regarding the statement delivered today :
Mr Erck talked about Novavax's " footprint " . He states , in part , :
--Vaccines like ours can be efficiently produced at massive scale to help meet global demand. Novavax vaccines are manufactured, transported, and stored at standard refrigeration temperatures. This is a very important feature as it helps simplify production, worldwide distribution, and use.
--In mid-2020 , " there were significant constraints on supplies, raw materials, and facilities with vaccine manufacturing capabilities. Novavax engaged in extensive partnerships and technology transfers to meet the challenges of these constraints. "
-- "Today, much of our supply chain is based in Europe. .... We have also partnered with organizations in Germany, Ireland, Belgium, Spain, Poland, and the Netherlands that will produce our final packaged product for European and global use. "
Now let's forward to Mr Erck's comments regarding " LESSONS LEARNED " . I encourage all Novavax shareholders to read very carefully . I will simply restate the following remark :
-- "Over the course of the pandemic, we spent months transferring know-how to our partners to ensure they can manufacture vaccine that meets regulators’ strict standards for safety and effectiveness. "
Not a single comment or reflection on what lessons were learned with regard to entering CONTRACTS for the manufacture of a vaccine in a large scale production environment . No thoughts regarding stockpiling and distribution procedures and expectations .
Monitoring adherence to all phase-appropriate good manufacturing practices . Unfortunately , many questions and concerns continue to prevail . What did Novavax learn about quality checks and contamination procedures and protocols ?
I will stop at this point .
Mr Erck, I applaud your attempt to detail lessens learned . However, I believe the " market " wants to see and understand a clear NOVAVAX vision of the pathway to the DELIVERY of safe and effective vaccines that assure confidence with the " identity , strength , quality and purity " of a drug to meet and exceed future public health challenges in a post EUA global environment .
With due respect Mr Erck , please tell us the lessons learned about company leadership SELLING thousands of Novavax stock shares when the company was attempting to bring a viable vaccine products to market .